Evidence map›Paper›PMID 41823675›Full record

ArticleJournal of Alzheimer's disease : JAD2026

FDG-PET imaging to identify brain regions associated with Alzheimer's disease-related TDP-43 proteinopathy: A predictive model using penalized logistic regression analysis.

Anna Lavrova, Ryota Satoh, Nirubol Tosakulwong, Stephen D Weigand, Clifford R Jack, Ronald C Petersen, Aivi T Nguyen, R Ross Reichard, Mercedes Prudencio, Leonard Petrucelli and 4 more

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anna LavrovaDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID 0009-0001-7521-7082
Ryota SatohDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Nirubol TosakulwongDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Stephen D WeigandDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Aivi T NguyenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
R Ross ReichardDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Mercedes PrudencioDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Leonard PetrucelliDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Val LoweDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2930-8634

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Project 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2014 to 2024
$17.6M
Expanding insights into FTD disease mechanismsR35NS097273 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2017 to 2024
$10.6M
Human Biomarkers CoreU54NS123743 · NINDS · STANFORD UNIVERSITY · PI FRATTA, PIETRO, GITLER, AARON D. · 2021 to 2025
$8.2M
Understanding the role of TDP-43 in Alzheimers disease and FTLDR01AG037491 · NIA · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A · 2010 to 2024
$6.5M
Investigating the role of TMEM106b genetics and pathology in Alzheimer’s disease, LATE and FTLDR01NS132330 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Keith A Josephs, LEONARD PETRUCELLI · 2023 to 2026
$4.3M
Stathmin-2 and TDP-43 neurodegeneration in Alzheimer’s and multi-etiology dementiasR01NS120992 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, PRUDENCIO, MERCEDES · 2024 to 2025
$1.6M
NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG037491NIA NIH HHS U01 AG006786NINDS NIH HHS P01 NS084974NINDS NIH HHS R01 NS120992NINDS NIH HHS R01 NS132330NINDS NIH HHS R35 NS097273NINDS NIH HHS U54 NS123743
6 · The paper itself

Abstract

BackgroundTAR DNA-binding protein 43 (TDP-43) proteinopathy contributes to Alzheimer's disease progression, but diagnosis remains autopsy-dependent.ObjectiveThis study aimed to develop a predictive model using FDG-PET imaging to identify brain regions associated with TDP-43 pathology in vivo.MethodsPenalized logistic regression analyzed data from 294 participants and a subset of 159 with Braak and Thal ≥4. Features included FDG standard uptake value ratios (SUVRs) from 123 brain regions and age. Participants were split into training (90%) and testing (10%) datasets, with significant predictors identified by non-zero coefficients at optimal lambda.ResultsThe model achieved 68% accuracy (AUC = 0.70) in 294 participants, highlighting the middle temporal gyrus, parahippocampal gyrus, and hippocampus. In the subset (n = 159), accuracy was 65% (AUC = 0.71), with the medial amygdala and precentral gyrus as key predictors of TDP-43 pathology.ConclusionsThis study suggests a moderate predictive accuracy of FDG-PET to identify brain regions associated with Alzheimer's disease-related TDP-43 proteinopathy.

Indexed as

Alzheimer DiseaseBrainFluorodeoxyglucose F18Positron-Emission TomographyTDP-43 ProteinopathiesAgedAged, 80 and overDNA-Binding ProteinsFemaleHumansLogistic ModelsMaleRadiopharmaceuticalsDNA-Binding ProteinsFluorodeoxyglucose F18RadiopharmaceuticalsAlzheimer's diseasebiomarkerfluorodeoxyglucoseLATE-NCPETTAR DNA-binding protein 43

Identifiers

PMID41823675
PMCPMC13185787

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.